Number 3: The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent ...
The Banking of Biosimilars: Insights From a Leading Health Economist ...
The Banking of Biosimilars: Insights From a Leading Health Economist ...
Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, ...
Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...
Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety and efficacy after being switched to another ranibizumab biosimilar, ...
The Banking of Biosimilars: Insights From a Leading Health Economist ...
Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback